Background:
- Heterogeneity in interleukin-1β (IL-1β) expression in nonsmall cell lung cancer (NSCLC) samples has been observed
- Despite the incidental finding of improved lung cancer incidence and mortality with the IL-1β inhibitor canakinumab, clinical trials such as CANOPY 1 and 2 failed to show improved outcomes with chemo/immunotherapy
- The clinical implications and interplay of oncogenic driver mutations and IL-1β in the setting of varying treatment modalities including immune-checkpoint inhibitors (ICIs) have not been previously explored
- The aim of this study is to evaluate the prognostic and predictive role of IL-1β in NSCLC with respect to driver mutations such as KRAS, EGFR, ERBB2, BRAF, STK11, and ALK fusion